The Interactions Between hERG Potassium Channel and Blockers

被引:17
作者
Du, Lupei [1 ,2 ,4 ]
Li, Minyong [3 ,4 ]
You, Qidong [1 ,2 ]
机构
[1] China Pharmaceut Univ, Dept Med Chem, Nanjing 210009, Peoples R China
[2] China Pharmaceut Univ, Jiangsu Key Lab Carcinogenesis & Intervent, Nanjing 210009, Peoples R China
[3] Georgia State Univ, Dept Chem, Atlanta, GA 30302 USA
[4] Shandong Univ, Sch Pharm, Dept Med Chem, Jinan 250012, Shandong, Peoples R China
关键词
hERG potassium channel; ligand-based; non-cardiac agents; receptor-based; LONG-QT-SYNDROME; RECTIFIER K+ CURRENT; I-KR; MOLECULAR DETERMINANTS; CRYSTAL-STRUCTURE; BINDING-SITE; DRUG; PREDICTION; INHIBITION; BLOCKADE;
D O I
10.2174/156802609788317829
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The human ether-a-go-go related gene (hERG) potassium channel is critical to the QT interval in the human heart measured by the electrocardiogram (ECG). The blockade of hERG would induce undesired lethal arrhythmia, named torsades de pointes (TdP), a rare but life-threatening symptom. Although a large number of experimental studies on hERG have been conducted so far, knowledge of how known ligands bind to hERG still remains sketchy and has been a major hindrance in the effort to designing novel medicinal molecules devoid of hERG activity in the hope of improving drug safety. This review summarizes several studies on ligand-hERG interactions by in silico receptor-based and ligand-based modeling approaches during recent years. These efforts could aid tremendously in understanding the determinants of ligand binding to hERG channel and the molecular basis of hERG channel blockade, and offer a more rational approach for the prediction of QT-prolongation liability and for the development of novel and safe non-cardiac agents.
引用
收藏
页码:330 / 338
页数:9
相关论文
共 66 条
[1]   Disease-associated mutations in KCNE potassium channel subunits (MiRPs) reveal promiscuous disruption of multiple currents and conservation of mechanism [J].
Abbott, GW ;
Goldstein, SAN .
FASEB JOURNAL, 2002, 16 (03) :390-400
[2]   Prediction of herg K+ blocking potency:: Application of structural knowledge [J].
Aptula, AO ;
Cronin, MTD .
SAR AND QSAR IN ENVIRONMENTAL RESEARCH, 2004, 15 (5-6) :399-411
[3]  
Aronov AM, 2008, CURR OPIN DRUG DISC, V11, P128
[4]   Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers [J].
Aronov, Alex M. .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (23) :6917-6921
[5]   A model for identifying HERG K+ channel blockers [J].
Aronov, AM ;
Goldman, BB .
BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (09) :2307-2315
[6]   HERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study [J].
Bains, W ;
Basman, A ;
White, C .
PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY, 2004, 86 (02) :205-233
[7]   A common antitussive drug, clobutinol, precipitates the long QT syndrome 2 [J].
Bellocq, C ;
Wilders, R ;
Schott, JJ ;
Louérat-Oriou, B ;
Boisseau, P ;
Le Marec, H ;
Escande, D ;
Baró, I .
MOLECULAR PHARMACOLOGY, 2004, 66 (05) :1093-1102
[8]   Drugs, hERG and sudden death [J].
Brown, AM .
CELL CALCIUM, 2004, 35 (06) :543-547
[9]   Crystal structure and functional analysis of the HERG potassium channel N terminus: A eukaryotic PAS domain [J].
Cabral, JHM ;
Lee, A ;
Cohen, SL ;
Chait, BT ;
Li, M ;
Mackinnon, R .
CELL, 1998, 95 (05) :649-655
[10]   Toward a pharmacophore for drugs inducing the long QT syndrome:: Insights from a CoMFA study of HERG K+ channel blockers [J].
Cavalli, A ;
Poluzzi, E ;
De Ponti, F ;
Recanatini, M .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (18) :3844-3853